ArticleBriefings in bioinformatics2026
Antibody-antigen neutralization prediction by integrating structural information distillation and physicochemical constraints.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Efficient and large-scale evaluation of antibody-antigen neutralization is critical for accelerating antibody drug development. To address this need, we propose SPAAN, a deep-learning framework that predicts neutralization directly from antibody and antigen sequences. Rather than relying on experimentally determined structures, SPAAN learns from structural knowledge and biologically relevant molecular properties during training, enabling accurate predictions using sequence information alone. On the SARS-CoV-2 neutralization dataset, SPAAN consistently outperforms existing state-of-the-art methods. The model also shows strong interpretability by capturing key interaction patterns underlying antibody-antigen recognition. Furthermore, on the HIV neutralization dataset, SPAAN achieves state-of-the-art performance in multiple challenging scenarios involving previously unseen antibodies or antigens, demonstrating robust generalization ability. Overall, SPAAN provides an accurate, interpretable, and broadly applicable framework for antibody-antigen neutralization prediction, offering a practical tool to support large-scale antibody engineering and therapeutic discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.